- By FYH News Team
[ad_1]
Women, Southerners, and Black and Hispanic Patients Denied Cholesterol-Lowering Medication More Often, Data Show
PR Newswire
WASHINGTON, June 9, 2022
New Report on Insurance Barriers for PCSK9 Inhibitors Featured at National Cardiovascular Health Policy Summit
WASHINGTON, June 9, 2022 /PRNewswire/ — New data show that health plans reject prescriptions for cholesterol-lowering medication for women, southerners, and Black and Hispanic patients more often than for white patients. The findings appear in “Rejected: How Life-Saving Heart Medication Eludes Women, Southerners, and People of Color,” a new policy brief from the Partnership to Advance Cardiovascular Health.
Key Findings
The report details 2019-2021 commercial insurance claims data for cholesterol-lowering PCSK9 inhibitors, which show that:
- Women are rejected 21% more often than men are
- Rejection rates in Arkansas are 67% higher than the national average, while rejection rates in Mississippi and Oklahoma are 29% higher than the national average
- Black patients face a 20% higher rejection rate than white patients
- Hispanic patients face a 25% higher rejection rate than white patients
Certain health plans reject a disproportionate number of claims. Of plans with at least 500 claims for PCSK9 inhibitors:
Some plans rejected three-fourths or more of claims:
- Moda Health Plan (87%)
- Maxor Plus (86%)
- Federal Employee Benefit Plan (75%)
Several plans rejected about half of claims:
- Blue Cross Blue Shield Arizona (51%)
- Blue Cross Blue Shield Mississippi (36%)
- Blue Cross Blue Shield Arkansas (45%)
“This information is concerning,” says cardiologist Dharmesh Patel, MD. “We see higher denial rates in communities that are already high risk for deadly cardiovascular events. Heart disease is the leading cause of death in the United States, and yet patients who most need FDA-approved medications to prevent adverse events are being denied.”
Patel is president of the Partnership to Advance Cardiovascular Health.
About PSCK9 Inhibitors
PCSK9 inhibitors, which first came to clinic in 2015, are:
- Injectable drugs designed to lower high LDL cholesterol
- Typically prescribed to patients who cannot get their LDL cholesterol down enough through statins alone
- Shown to decrease LDL cholesterol by up to 70% and cut the risk of a heart attack by almost one-third
Manufacturers slashed the drugs’ price by 60% in 2019, yet some insurers continue to block access.
The findings were announced during the fifth annual Cardiovascular Health Policy Summit hosted by the Partnership to Advance Cardiovascular Health. Patient advocates, clinicians, and policymakers gathered to discuss the barriers patients face in accessing these cholesterol-lowering drugs.
SOURCE Partnership to Advance Cardiovascular Health
[ad_2]
Source link
Trending Topics
Features
- Drive Toolkit
Download and distribute powerful vaccination QI resources for your community.
- Health Champions
Sign up now to support health equity and sustainable health outcomes in your community.
- Cancer Early Detection
MCED tests use a simple blood draw to screen for many kinds of cancer at once.
- PR
FYHN is a bridge connecting health information providers to BIPOC communities in a trusted environment.
- Medicare
Discover an honest look at our Medicare system.
- Alliance for Representative Clinical Trials
ARC was launched to create a network of community clinicians to diversify and bring clinical trials to communities of color and other communities that have been underrepresented.
- Reducing Patient Risk
The single most important purpose of our healthcare system is to reduce patient risk for an acute event.
- FYH News Team
- Subash Kafle
- Subash Kafle
